- Bloomberg•3 days ago
The U.S. Food and Drug Administration noted incomplete laboratory records among potential manufacturing violations it observed during an inspection of Sun Pharmaceutical Industries Ltd.’s Dadra unit this ...
- Reuters•last month
India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. Cut-price generics sold by India's small- and medium-sized drugmakers have been critical in bringing down prices there. A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said.
- Bloomberg•last month
Now they just have to survive Dr. Trump's trade prescriptions.
SUNPHARMA.NS : Summary for SUN PHARMACEUTICAL INR1(DEMAT) - Yahoo Finance
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Real Time Price. Currency in INR
Add to watchlist
|Day's Range||636.60 - 659.45|
|52 Week Range||571.90 - 854.95|
|PE Ratio (TTM)||20.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|